Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

922 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Among authors: fenaux p. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). Mounier N, et al. Ann Oncol. 2014 Aug;25(8):1622-8. doi: 10.1093/annonc/mdu189. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827123 Free article. Clinical Trial.
High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine.
Tiso F, In 't Hout FEM, Knops R, Kroeze LI, van Rooij A, van de Loosdrecht AA, Westers TM, Langemeijer SMC, Preudhomme C, Duployez N, Fenaux P, Kosmider O, Bouscary D, de Graaf AO, Martens JHA, van der Reijden BA, Adès L, Fontenay M, Jansen JH. Tiso F, et al. Among authors: fenaux p. Hemasphere. 2025 Jan 3;9(1):e70034. doi: 10.1002/hem3.70034. eCollection 2025 Jan. Hemasphere. 2025. PMID: 39760001 Free PMC article. No abstract available.
FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.
Peterlin P, Gaschet J, Turlure P, Gourin MP, Dumas PY, Thepot S, Berceanu A, Park S, Hospital MA, Cluzeau T, Torregrosa-Diaz JM, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Jullien M, Fenaux P, Chevallier P. Peterlin P, et al. Among authors: fenaux p. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286025. Online ahead of print. Haematologica. 2024. PMID: 39568426 Free article.
FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.
Desterke C, Bilhou-Nabéra C, Guerton B, Martinaud C, Tonetti C, Clay D, Guglielmelli P, Vannucchi A, Bordessoule D, Hasselbalch H, Dupriez B, Benzoubir N, Bourgeade MF, Pierre-Louis O, Lazar V, Vainchenker W, Bennaceur-Griscelli A, Gisslinger H, Giraudier S, Le Bousse-Kerdilès MC; French Intergroup of Myeloproliferative Disorders,; French INSERM; European EUMNET Networks on Myelofibrosis. Desterke C, et al. Cancer Res. 2011 Apr 15;71(8):2901-15. doi: 10.1158/0008-5472.CAN-10-1731. Epub 2011 Apr 12. Cancer Res. 2011. PMID: 21487043
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, McAvoy C, Lacombe V, Ardois S, Campochiaro C, Maria A, Coustal C, Comont T, Lazaro E, Lifermann F, Le Guenno G, Lobbes H, Grobost V, Outh R, Campagne J, Dor-Etienne A, Garnier A, Jamilloux Y, Dossier A, Samson M, Audia S, Nicolas B, Mathian A, de Maleprade B, De Sainte-Marie B, Faucher B, Bouaziz JD, Broner J, Dumain C, Antoine C, Carpentier B, Castel B, Lartigau-Roussin C, Crickx E, Volle G, Fayard D, Decker P, Moulinet T, Dumont A, Nguyen A, Aouba A, Martellosio JP, Levavasseur M, Puigrenier S, Antoine P, Giraud JT, Hermine O, Lacout C, Martis N, Karam JD, Chasset F, Arnaud L, Marianetti P, Deligny C, Chazal T, Woaye-Hune P, Roux-Sauvat M, Meyer A, Sujobert P, Hirsch P, Abisror N, Fenaux P, Kosmider O, Jachiet V, Fain O, Terrier B, Mekinian A, Georgin-Lavialle S; FRENVEX. Hadjadj J, et al. Among authors: fenaux p. Ann Rheum Dis. 2024 Sep 30;83(10):1358-1367. doi: 10.1136/ard-2024-225640. Ann Rheum Dis. 2024. PMID: 38777378
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.
Rombaut D, Sandmann S, Tekath T, Crouch S, de Graaf AO, Smith A, Painter D, Kosmider O, Tobiasson M, Lennartsson A, van der Reijden BA, Park S, D'Aveni M, Slama B, Clappier E, Fenaux P, Adès L, van de Loosdrecht A, Langemeijer S, Symeonidis A, Čermák J, Preudhomme C, Savic A, Germing U, Stauder R, Bowen D, van Marrewijk C, Bernard E, de Witte T, Varghese J, Hellström-Lindberg E, Dugas M, Martens J, Malcovati L, Jansen JH, Fontenay M; MDS‐RIGHT consortium. Rombaut D, et al. Among authors: fenaux p. Hemasphere. 2025 Jan 22;9(1):e70073. doi: 10.1002/hem3.70073. eCollection 2025 Jan. Hemasphere. 2025. PMID: 39850648 Free PMC article.
Nonischemic Cardiac Manifestations in VEXAS Syndrome.
Robert M, Mathian A, Lacombe V, Lobbes H, Adélaïde L, Le Besnerais M, Dacher JN, Terrier B, Mékinian A, Bourguiba R, Georgin-Lavialle S; FRENVEX Group. Robert M, et al. JAMA Netw Open. 2024 Dec 2;7(12):e2450251. doi: 10.1001/jamanetworkopen.2024.50251. JAMA Netw Open. 2024. PMID: 39666342 Free PMC article.
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia.
Deschamps P, Wacheux M, Gosseye A, Morabito M, Pagès A, Lyne AM, Alfaro A, Rameau P, Imanci A, Chelbi R, Marchand V, Renneville A, Patnaik MM, Lapierre V, Badaoui B, Wagner-Ballon O, Berthon C, Braun T, Willekens C, Itzykson R, Fenaux P, Thépot S, Etienne G, Elvira-Matelot E, Porteu F, Droin N, Perié L, Laplane L, Solary E, Selimoglu-Buet D. Deschamps P, et al. Among authors: fenaux p. J Clin Invest. 2024 Sep 17;134(22):e180738. doi: 10.1172/JCI180738. J Clin Invest. 2024. PMID: 39545419 Free PMC article.
922 results